__timestamp | Bio-Techne Corporation | Merck & Co., Inc. |
---|---|---|
Wednesday, January 1, 2014 | 106352000 | 16768000000 |
Thursday, January 1, 2015 | 144969000 | 14934000000 |
Friday, January 1, 2016 | 162364000 | 13891000000 |
Sunday, January 1, 2017 | 188462000 | 12775000000 |
Monday, January 1, 2018 | 210850000 | 13509000000 |
Tuesday, January 1, 2019 | 240515000 | 14112000000 |
Wednesday, January 1, 2020 | 255497000 | 13618000000 |
Friday, January 1, 2021 | 298182000 | 13626000000 |
Saturday, January 1, 2022 | 349103000 | 17411000000 |
Sunday, January 1, 2023 | 366887000 | 16126000000 |
Monday, January 1, 2024 | 389335000 |
Cracking the code
In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for two industry giants: Merck & Co., Inc. and Bio-Techne Corporation, from 2014 to 2023.
Merck & Co., Inc., a stalwart in the pharmaceutical industry, has seen its cost of revenue fluctuate, peaking in 2014 and 2022. Notably, 2022 marked a significant increase, with costs rising by approximately 36% compared to 2017. Meanwhile, Bio-Techne Corporation, a leader in biotechnology, has experienced a steady upward trajectory in its cost of revenue, with a remarkable 266% increase from 2014 to 2023.
While Merck's data for 2024 remains elusive, Bio-Techne continues its upward trend, underscoring its growth strategy. This comparative analysis offers a window into the financial strategies shaping these industry leaders.
Johnson & Johnson vs Merck & Co., Inc.: Efficiency in Cost of Revenue Explored
Merck & Co., Inc. vs Zoetis Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Analyzing Cost of Revenue: Merck & Co., Inc. and Corcept Therapeutics Incorporated
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Merck & Co., Inc. vs MorphoSys AG
Amgen Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Gilead Sciences, Inc. and Bio-Techne Corporation's Expenses
United Therapeutics Corporation vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Viridian Therapeutics, Inc.